Last reviewed · How we verify
NCT07030790
A Phase I Clinical Study of a Single Dose of KLA480
Phase 1 trial testing KLA480 injection in Healthy Participants in 20 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 17 May 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 1 March 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- KLA480 injection — full drug profile →
- Placebo
Conditions studied
- Healthy Participants — all drugs for Healthy Participants →
Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. — full company profile →
Who can join
Adults 18 to 45, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary purpose: To evaluate the safety and tolerability of KLA480 injection after a single subcutaneous injection in healthy participants. Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of KLA480 injection after a single subcutaneous injection in healthy participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07030790
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Participants
Currently open trials in the same condition.
- NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
- NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
- NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
- NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
- NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
Other Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. trials
Trials by the same sponsor.
- NCT07448922 — A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors · Phase 2 · not yet recruiting
- NCT06674694 — The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting In · Phase 1 · recruiting
- NCT05906537 — SKB410 for Injection in Solid Tumors · Phase 1 · active not recruiting
- NCT05631262 — SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors · Phase 2 · active not recruiting
- NCT05496426 — A Study of KL130008 in Adults With Severe Alopecia Areata · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07030790 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
- Last refreshed: 22 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07030790.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing